FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

Overview of attention for article published in Oncologist, August 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,638 followers.

When drug approval, from bench to bedside, is ~14.5 years, Pfizer's crizotinib is a star - 6 years to FDA approval! http://t.co/iuna18solb

"FDA Approval: Crizotinib for Metastatic NSCLC With Anaplastic Lymphoma Kinase Rearrangements" The oncologist http://t.co/oW930pPYDW

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.